Thienopyrrole acetic acids as antagonists of the CRTH2 receptor
摘要:
The bioisosteric replacement of the indole core of CRTH2 antagonists using thienopyrroles was investigated, resulting in potent antagonists with good selectivity over DP1. Early ADME/PK assessment of this chemotype demonstrated bioavailability in mice. (C) 2011 Elsevier Ltd. All rights reserved.
I(III)-Catalyzed Oxidative Cyclization–Migration Tandem Reactions of Unactivated Anilines
作者:Tianning Deng、Emily Shi、Elana Thomas、Tom G. Driver
DOI:10.1021/acs.orglett.0c03497
日期:2020.11.20
An I(III)-catalyzed oxidative cyclization–migration tandem reaction using Selectfluor as the oxidant was developed that converts unactivated anilines into 3H-indoles is reported herein. The reaction requires as little as 1 mol % of the iodocatalyst and is mild, tolerating pyridine and thiophene functional groups, and the dependence of the diastereoselectivity of the process on the identity of the iodoarene
[EN] HSP90 MODULATING COMPOUNDS, COMPOSITIONS, METHODS AND USES<br/>[FR] COMPOSÉS MODULATEURS DE LA HSP90, COMPOSITIONS, PROCÉDÉS ET UTILISATIONS CORRESPONDANTS
申请人:AEGERA THERAPEUTICS INC
公开号:WO2011035416A1
公开(公告)日:2011-03-31
The invention relates to therapeutic compounds which bind to HSP90, said compounds containing a benzamide group bound to a tricyclic condensed ring system via the nitrogen atom of a pyrrole located in the center of the condensed system. The compounds disclosed herein bind HSP90 and alter the chaperoning capability of HSP90 proteins. Intermediate benzonitrile compounds which are precursors to the benzamide compounds are also disclosed. The invention also relates to pharmaceutical compositions comprising these compounds, and methods of treating diseases and disorders such as cancer, autoimmune diseases and other diseases.
Thienopyrroles and pyrrolothiazoles as new therapeutic agents
申请人:Bonafoux Dominique F.
公开号:US20090209609A1
公开(公告)日:2009-08-20
The present invention is directed to novel compounds of Formula (I)
wherein the variables are defined as herein. The compounds of Formula (I) are useful as CRTH2 antagonists and as such would be useful in treating certain conditions and diseases, especially asthma, allergic asthma, allergic inflammation, rhinitis, allergic rhinitis or atopic dermatitis.
A simple access to silylated and germylated binuclear heterocycles, based on an original anionic rearrangement, is described. A set of electron‐rich and electron‐poor silylated aromatic and heteroaromatic substrates were tested to understand the mechanism and the factors controlling this rearrangement, in particular its regioselectivity. This parameter was shown to follow the rules proposed before